← 홈

폐암 (NSCLC)

365개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 365개
AntibodyETOP IBCSG Partners Foundationderuxtecan (Arm 4), followe…Phase 3

durvalumab (Imfinzi, Adjuvant durvalumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+4
효능 ORR 45%임상시험 31상태 RECRUITING
CGTBiologicLiaoning Medical Diagnosis and …designPhase 2

Autologous immune Cells (Autologous immune Cells)

Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic) · Lung Cancer (Locally Advanced or Metasta

#LungCancerLocallyAdvancedorMetas#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 31상태 RECRUITING
AntibodyMerck Sharp & Dohme LLCADCsPhase 3

H1 receptor antagonist (H1 receptor antagonist)

Ovarian Cancer; Fallopian Tube Cancer · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase3#항체#면역항체+5
효능 ORR 6%임상시험 31상태 RECRUITING
AntibodyMerck Sharp & Dohme LLCPhase 3

H2 receptor antagonist (H2 receptor antagonist)

Ovarian Cancer; Fallopian Tube Cancer · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase3#항체#면역항체+4
임상시험 31상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

Neurokinin-1 receptor antagonist (Neurokinin-1 receptor antagonist)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 31상태 RECRUITING
AntibodystaleJiangsu Hansoh Pharmaceutical C…Phase 2

adebrelimab and chemotherapy (adebrelimab and chemotherapy)

Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer · Efficacy and Safety of Neoadjuvant Immun

#EfficacyandSafetyofNeoadjuvantIm#Antibody#Phase2#항체#면역항체+2
임상시험 31상태 RECRUITING
ADCBiologicstaleCullinan Therapeutics Inc.Phase 1

Dato-DXd (Datopotamab deruxtecan-dlnk, Datopotamab deruxtecan-dlnk (Dato-DXd))

Advanced Solid Tumor; NSCLC · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 74%임상시험 30상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

Vistusertib (Vistusertib)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 9.5%임상시험 30상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 3

DS-1062a (DS-1062a)

Non-small Cell Lung Cancer · Metastatic Lung Cancer

#MetastaticLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 74%임상시험 28상태 ACTIVE
AntibodystaleAstraZenecaPhase 2

Oleclumab (Oleclumab)

Non-small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 56.5%임상시험 28상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Patritumab Deruxtecan (Patritumab Deruxtecan)

Lung Neoplasm Malignant · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 28상태 RECRUITING
ADCBiologicstaleEMD Serono Research & Developme…Phase 2

Tepotinib (Tepotinib)

Non-small Cell Lung Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 54.7%임상시험 28상태 ACTIVE
ADCBiologicstaleBristol-Myers SquibbPhase 3

Amrubicin (Amrubicin)

Lung Cancer · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 80%임상시험 25상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

AZD2936 (AZD2936)

Advanced or Metastatic NSCLC · Advanced or Metastatic NSCLC

#AdvancedorMetastaticNSCLC#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 24상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 1

FL-DP (HER3-DXd, HER3-DXd (FL-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 24상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 2

Necitumumab (Necitumumab)

Squamous Cell Carcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 76%임상시험 23상태 DISCONTINUED
AntibodystalePfizerPhase 1

sasanlimab (sasanlimab)

Carcinoma, Pancreatic Ductal; Colorectal Neoplasms · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase1#항체#면역항체+5
효능 ORR 33.3%임상시험 23상태 DISCONTINUED
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

HER3-DXd (HER3-DXd)

Carcinoma, Non-Small-Cell Lung · HER3

#HER3#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 56%임상시험 22상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 1

CTM-1 Lyo-DP (HER3-DXd, HER3-DXd (CTM-1 Lyo-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 22상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 1

CTM-3 Lyo-DP (HER3-DXd, HER3-DXd (CTM-3 Lyo-DP))

Non-Small Cell Lung Cancer (NSCLC) · HER3

#HER3#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 22상태 RECRUITING

4 / 19 페이지

← 이전다음 →